Immuneering’s pancreatic cancer pill continues to beat standard care, updated first line data show

Immuneering’s oral pancreatic cancer therapy demonstrated an overall survival rate of 64% at one year when used as the initial treatment, the company said Wednesday. This is notably better than standard of care, and Immuneering ...